CalciMedica, Inc. Common Stock (CALC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CalciMedica, Inc. Common Stock (CALC) has a cash flow conversion efficiency ratio of 0.731x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.85 Million) by net assets ($-6.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is CalciMedica, Inc. Common Stock worth for the company's overall valuation and market capitalisation.
CalciMedica, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how CalciMedica, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CalciMedica, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CalciMedica, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore how high is CalciMedica, Inc. Common Stock's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TWZ Corporation Public Company Limited
BK:TWZ
|
-0.005x |
|
Greentech Metals Ltd
AU:GRE
|
-0.056x |
|
Medadvisor Ltd
AU:MDR
|
5.093x |
|
Crescent NV
BR:OPTI
|
-0.688x |
|
RENEWABLE VENTURES NORDIC
F:X72
|
-0.145x |
|
Meta Epsi Tbk PT
JK:MTPS
|
0.244x |
|
Income Asset Management Group Ltd
AU:IAM
|
-2.381x |
|
Spineguard
PA:ALSGD
|
-0.172x |
Annual Cash Flow Conversion Efficiency for CalciMedica, Inc. Common Stock (2018–2025)
The table below shows the annual cash flow conversion efficiency of CalciMedica, Inc. Common Stock from 2018 to 2025. View CALC live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.64 Million | $-21.18 Million | 3.189x | +317.31% |
| 2024-12-31 | $14.41 Million | $-21.15 Million | -1.467x | +53.48% |
| 2023-12-31 | $8.16 Million | $-25.73 Million | -3.154x | -347.72% |
| 2022-12-31 | $-9.23 Million | $-11.76 Million | 1.273x | +362.85% |
| 2021-12-31 | $65.02 Million | $-31.50 Million | -0.484x | -43.21% |
| 2020-12-31 | $94.79 Million | $-32.06 Million | -0.338x | +69.21% |
| 2019-12-31 | $28.41 Million | $-31.21 Million | -1.099x | +53.20% |
| 2018-12-31 | $12.02 Million | $-28.22 Million | -2.348x | -- |
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxi… Read more